281results about How to "Large dose" patented technology

In a method and device for producing a tomosynthetic 3D x-ray image, a number of 2D projection images of an examination subject are acquired using a fixed x-ray source. The x-ray source has multiple, individually controllable emitters that respectively emit a single x-ray dose from various different directions. The tomosynthetic 3D image is reconstructed from the individual 2D projection images, and at least one 2D projection image is composed of multiple individual images.

A non-gelatin encapsulation system for liquid filled soft capsules, by nature of the carrier, the cationic-ionic balance of the carrier and the active ingredients, or the concentration of the active ingredients and excipients, are difficult or impossible to commercially encapsulate in gelatin capsules. In particular, the system is adapted for the encapsulation of highly basic, or alkaline, fills. The system provides for a predominantly starch and gelling carrageenan based shell, which displays high resistance to both concentrated fills and to alkaline fills, in particular, to those fills which contain the salt or salts of weak acids and strong bases.

Pharmaceutical compositions of (R)-pramipexole and methods and kits of using such compositions for the treatment of neurodegenerative diseases, or those related to mitochondrial dysfunction or increased oxidative stress are disclosed.

A Chinese medicine in the form of plaster for treating rheumatic arthritis, hyperosteogeny, cervical spondylopathy, lumbar intervertebral disk protrusion, and muscle and bone injury is prepared from 56 Chinese-medicinal materials including camphor, pinellia tuber, hot pepper, toad venom, etc. Its advantage is high curative effect.

The invention discloses a preparation method of traditional Chinese medicine ultrafine formula particles. The preparation method comprises the following steps that: single Chinese medicinal material or traditional Chinese medicine decoction pieces are partially ultrafine-crushed into ultrafine powder, the other parts are coarse-crushed, extracted, concentrated, dried and crushed to obtain dry extract powder, the ultrafine powder and auxiliary materials are added to obtain mixture, and the obtained mixture is mixed uniformly, palletized, granulated and subpackaged. The traditional Chinese medicine ultrafine formula particles is characterized in that the characteristics of the traditional Chinese medicine ultrafine decoction pieces of saving medicine materials and being controllable in quality and convenient in administration. Compared with the traditional Chinese medicine formula particles, the preparation method better preserves the medicinal properties of the traditional Chinese medicines, has the advantages of little used amount of auxiliary materials, convenient identification, benefit to measuring the content of index ingredients, preserves the advantages that the traditional Chinese medicine decoction piece can be added and reduced according to the disease and the traditional decoction has unique curative effect, also overcomes the defects of troublesome decoction and inconvenient administration, and has advanced technique and controllable quality. The invention also discloses a processing method of the Chinese medicinal material, which extracts the raw medicinal materials partially, carries out ultrafining treatment partially and then carries out mixing. The method can obvious improve the utilization ratio and leachability of the Chinese medicinal materials.

The invention relates to a method for producing a multi-layer collagen scaffold. The method generally comprises the steps of: preparing a first suspension of collagen and freezing or lyophilising the suspension to provide a first layer; optionally preparing a further suspension of collagen and adding the further suspension onto the layer formed in the previous step to form a further layer, and freezing or lyophilising the layers, wherein when the layer formed in the previous step is formed by lyophilisation the lyophilised layer is re-hydrated prior to addition of the next layer; optionally, repeating the aforementioned step to form one or more further layers; and preparing a final suspension of collagen and pouring the final suspension onto the uppermost layer to form a final layer, and freeze-drying the layers to form the multilayer collagen composite scaffold.

The invention relates to an aryl [a] indole [2,3-g] quinolizine compound as well as a preparation method, a pharmaceutical composition and application thereof, and particularly relates to a aryl [a] indole [2,3-g] quinolizine compound with a novel structure as shown in a general formula (I) and a derivative, a preparation method and a pharmaceutical composition thereof and application of the aryl [a] indole [2,3-g] quinolizine compound in preparation of a drug for treating diseases related to alpha 1-adrenoreceptor and urinary system diseases, such as benign prostatic hyperplasia, uroschesis and bladder outlet obstruction, especially.

The present invention discloses a Yinhuang powder injection for intravenous injection and its preparation process. The formula includes honeysuckle extractive in 0.1-0.3 weight portions and skullcap root extractive in 0.1-0.6 weight portions. The preparation process includes the steps of dissolution of honeysuckle extractive and skullcap root extractive in water solution of sodium hydroxide, heating to slightly boiling for 15-20 min, filtering, disinfection, refrigerating for one week, pressurized filtering, freeze drying or spray drying for the filtrate liquid to obtain the said powder.

Methods of treating a food allergy, allergic reactions, hypersensitivity, inflammatory responses, inflammation are provided. In one method, histamine releasing factor (HRF)/translationally controlled tumor protein (TCTP) is contacted with a compound that inhibits or reduces binding of HRF/TCTP to an immunoglobulin in order to treat the food allergy, allergic reaction, hypersensitivity, inflammatory response, or inflammation. Methods of reducing or decreasing the probability, severity, frequency, duration or preventing a subject from having an acute or chronic food allergy, allergic reaction, hypersensitivity, an inflammatory response or inflammation, are also provided. In one method, histamine releasing factor (HRF)/translationally controlled tumor protein (TCTP) is contacted with a compound that inhibits or reduces binding of HRF/TCTP to an immunoglobulin in order to reduce or decrease the probability, severity, frequency, duration or prevent a subject from having an acute or chronic food allergy, allergic reaction, hypersensitivity, an inflammatory response or inflammation.

The present invention is directed to pharmaceutical compositions containing (a) a dosage of a non-steroidal anti-inflammatory drug (NSAID) effective to induce analgesia an anti-inflammatory effect, or an anti-pyretic effect and (b) a beta-cyclodextrin compound; wherein the dosage of the NSAID compound is less than the minimum approved dose for the route of administration. Additionally, the present invention is directed to methods for treating a mammal in need of an analgesic, an anti-inflammatory, or an anti-pyretic agent comprising administering the pharmaceutical composition of the present invention.

A compound for inhibiting beta-starch protein aggregation and fibrillation or its medicinal accepted slat, composition, its production and use in prevention and treatment of Alzheimer's disease are disclosed. The compound or medicinal accepted slat combines with Alpha-beta polypeptide and inhibits Alpha-beta polypeptide aggregation and fibrillation.

Charged nutritive proteins are provided. In some embodiments the nutritive proteins an aqueous solubility of at least 12.5 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 50 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 100 g/L at pH 7. In some embodiments the nutritive proteins comprise at least one of a level of a) a ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of branch chain amino acid residues to total amino acid residues present in a benchmark protein; b) a ratio of leucine residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of leucine residues to total amino acid residues present in a benchmark protein; and c) a ratio of essential amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of essential amino acid residues to total amino acid residues present in a benchmark protein. Also provided are nucleic acids encoding the proteins, recombinant microorganisms that make the proteins, methods of making the proteins using recombinant microorganisms, compositions that comprise the proteins, and methods of using the proteins, among other things.